Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -4.36% | 352.43 | 0.0% | $5529.05m | |
| BNTX | BioNTech SE | -2.97% | 351.74 | 0.0% | $1554.09m | |
| NVAX | Novavax, Inc. | 7.56% | 208.63 | 78.2% | $1149.83m | |
| AMGN | Amgen, Inc. | -2.26% | 198.88 | 1.4% | $591.30m | |
| LGVN | Longeveron Inc. | 0.04% | 26.26 | 0.0% | $511.78m | |
| GILD | Gilead Sciences, Inc. | -2.44% | 68.93 | 1.0% | $497.91m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.73% | 636.53 | 2.7% | $490.45m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.67% | 186.94 | 1.9% | $375.32m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 0.88% | 4.61 | 0.7% | $322.26m | |
| ILMN | Illumina, Inc. | -1.48% | 365.33 | 3.3% | $311.28m | |
| OCGN | Ocugen, Inc. | -1.40% | 6.34 | 0.0% | $293.70m | |
| BIIB | Biogen, Inc. | -0.16% | 235.74 | 1.8% | $289.61m | |
| EXAS | EXACT Sciences Corp. | -1.39% | 85.37 | 18.0% | $167.68m | |
| INCY | Incyte Corp. | -3.77% | 67.72 | 2.4% | $165.57m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -1.27% | 86.29 | 4.2% | $144.64m |
Company Profile
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.